The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1529
Issue 1529
Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes; Prasterone (Intrarosa) for Dyspareunia; Safinamide (Xadago) for Parkinson's Disease; Deflazacort (Emflaza) for Duchenne Muscular Dystrophy; Correction: Drugs for Helicobacter pylori Infection
The full issue is available to subscribers Subscriber Login   
Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes

The FDA has approved Xultophy 100/3.6 (Novo Nordisk), a fixed-ratio combination of insulin degludec and the GLP-1 (glucagon-like peptide-1) receptor agonist liraglutide, for once-daily treatment of adults with type 2 diabetes inadequately controlled on basal insulin (<50 units daily) or liraglutide (≤1.8 mg daily).

Soliqua 100/33, a long-acting insulin/GLP-1 receptor agonist combination that contains insulin glargine (Lantus, and others) and lixisenatide (Adlyxin), has also recently become available in the US.1 

GLP-1 RECEPTOR AGONISTS — GLP-1 receptor agonists lower glucose levels by potentiating glucose-dependent insulin secretion, suppressing postprandial glucagon secretion, slowing gastric emptying, and promoting satiety. They lower glycated hemoglobin (A1C) by about 1-1.5%, have been associated with weight loss of 1.5-2.8 kg, ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this issue:
Title: Issue 1529
Select version:
 Downloadable, electronic issue - $35
 Postal, hardcopy issue - $35